Neill Moray MacKenzie

Biotecnol-Serviços e Desenvolvimento SA engages in the discovery, engineering, and development of multifunctional antibody molecules, directed to key therapeutic targets. The firm operates as a biopharmaceutical company working in the field of immuno-oncology. It uses Tribody technology to develop a pipeline of in-house discovered products in selected oncology indications. The company was founded in 1997 and is headquartered in Oeiras, Portugal.

Biotecnol Ltd. engages in research & development of immuno-oncology antibody products. It specializes in recombinant antibodies, T cell engaging, multispecific antibodies and oncology. The company is headquartered in London, the United Kingdom.

Trimunocor Ltd. is a private company based in Harpenden, UK that focuses on developing ground-breaking solutions to protect premature neonates from chronic lung disease. Trimunocor is a spin-out based on IP from the Medical Research Council and University of Southampton. The British company's website provides information about their solution and their focus, as well as news and events. Visitors can also subscribe to stay up to date with the latest developments. The company was founded by Neill Moray MacKenzie and Howard Clark, with Neill Moray MacKenzie serving as CEO since incorporation.

Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK